Literature DB >> 3366218

Prognostic relevance of serum-markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas.

U Martinsson1, B Glimelius, H Hagberg, C Sundström.   

Abstract

The prognostic relevance of 4 different serum markers (deoxythymidine kinase = S-TK, lactic dehydrogenase = S-LDH, S-Haptoglobin and S-Orosomucoid) in relation to histopathology according to the Kiel classification, stage and presence or absence of initial symptoms were investigated in 168 consecutive cases of low-grade non-Hodgkin lymphomas (NHL). All serum markers, as well as the other three parameters, gave prognostic information. Univariate analysis yielded a high predictive value (p less than 0.0002) for both S-TK and S-LDH. The best information regarding the probability of survival was, however, obtained from the presence or absence of symptoms from lymphoma manifestations other than those caused by a strictly local tumor mass. Since S-TK and S-LDH correlated well with each other, only the better of them, S-TK, gave information additional to initial symptoms in a multivariate test.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3366218     DOI: 10.1111/j.1600-0609.1988.tb00180.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

Review 1.  Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.

Authors:  M Hallek; L Wanders; S Strohmeyer; B Emmerich
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

2.  Long-term outcome of follicular low-grade lymphoma. A report of 91 patients.

Authors:  P Morel; B Dupriez; I Plantier-Colcher; B Gosselin; C Declercq; J P Pollet; F Bauters
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

3.  Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.

Authors:  S Rehn; J S Gronowitz; C Källander; C Sundström; B Glimelius
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.